The company said total sales in the Biotechnology segment fell 18.0% over 3 months ended March 29, 2024, and its operating profit margin declined 1,070 basis points. It attributed the high-teens year-over-year decline in bioprocessing core sales mainly to lower demand as customers reduced their inventory levels.

1. 01

   The company said total sales in the Biotechnology segment fell 18.0% over 3 months ended March 29, 2024, and its operating profit margin declined 1,070 basis points. It attributed the high-teens year-over-year decline in bioprocessing core sales mainly to lower demand as customers reduced their inventory levels.

2. 02

   Danaher said its operating profit margin fell from 25.5% for the 3 months ended March 31, 2023 to 22.6% for the 3 months ended March 29, 2024, a decline of 290 basis points. It cited as unfavorable factors lower core sales in Q1, product mix and reduced leverage in its operational and administrative cost structure (170 basis points), and the acquisition-related fair value adjustment to inventory for the Abcam acquisition (40 basis points).

3. 03

   The company said net cash provided by operating activities from continuing operations for the first 3 months of 2024 was about $1.7 billion, a decrease of $67 million (4%) from the prior-year period. It said it held about $7.0 billion in cash and cash equivalents as of March 29, 2024.

4. 04

   Danaher said total sales in the Diagnostics segment rose 6.5% over 3 months ended March 29, 2024, and its operating profit margin increased 430 basis points. The company cited core sales growth as the main driver of the sales increase, in particular higher core sales of molecular diagnostics tests.

Key figures

Quarter ended March 29, 2024

Revenue

$5.8B

Operating income

$1.3B

Net income

$1.1B

EPS

$1.45

Gross profit

$3.5B

Operating cash flow

$1.7B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.